Energenesis Biomedical CO.,LTD.
Taiwan Stock ExchangeTotal Valuation
Energenesis Biomedical CO.,LTD. carries a market capitalization of 3.17B, placing it among publicly traded companies globally. Its enterprise value stands at 2.97B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 3.17B |
| Enterprise Value | 2.97B |
Share Statistics
Energenesis Biomedical CO.,LTD. currently has 87.98M shares outstanding.
| Shares Outstanding | 87.98M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 494.88, and the price-to-book ratio stands at 9.53.
| PE Ratio | N/A |
| PS Ratio | 494.88 |
| PB Ratio | 9.53 |
| P/TBV Ratio | 4.24 |
| P/FCF Ratio | -17.26 |
| P/OCF Ratio | -17.08 |
Enterprise Valuation
| EV / Sales | 387.60 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Energenesis Biomedical CO.,LTD. maintains a current ratio of 19.91, meaning it holds 19.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.66, indicating elevated leverage, while an interest coverage ratio of -594.55 demonstrates limited ability to service its debt obligations.
| Current Ratio | 19.91 |
| Quick Ratio | 19.30 |
| Debt / Equity | 1.66 |
| Debt / EBITDA | -0.05 |
| Interest Coverage | -594.55 |
Financial Efficiency
| Return on Equity (ROE) | -48.15 |
| Return on Assets (ROA) | -29.88 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.28 |
Stock Price Statistics
Energenesis Biomedical CO.,LTD.'s stock has declined approximately -39.93344% over the past 52 weeks. The 50-day moving average sits at 38.25, while the 200-day moving average is 43.99.
| Beta (5Y) | N/A |
| 52-Week Price Change | -39.93344% |
| 50-Day Moving Average | 38.25 |
| 200-Day Moving Average | 43.99 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Energenesis Biomedical CO.,LTD. generated 7.67M in revenue and converted that into -258.40M in net income, yielding earnings per share of -2.93. EBITDA reached -275.27M, while operating income came in at -275.27M.
| Revenue | 7.67M |
| Gross Profit | 5.83M |
| Operating Income | -275.27M |
| Pretax Income | -258.40M |
| Net Income | -258.40M |
| EBITDA | -275.27M |
| EBIT | -275.27M |
| Earnings Per Share (EPS) | -2.93 |
Balance Sheet
Energenesis Biomedical CO.,LTD. holds 838.10M in cash and equivalents against 14.84M in total debt, resulting in a net debt position of -673.10M. Total book value stands at 398.60M, with working capital of 821.01M providing operational flexibility.
| Cash & Cash Equivalents | 838.10M |
| Total Debt | 14.84M |
| Net Debt | -673.10M |
| Equity (Book Value) | 398.60M |
| Book Value Per Share | 4.51 |
| Working Capital | 821.01M |
Cash Flow
Energenesis Biomedical CO.,LTD. produced -222.41M in operating cash flow over the past twelve months. After subtracting -2.32M in capital expenditures, free cash flow totaled -224.73M - equivalent to -2.54 per share.
| Operating Cash Flow | -222.41M |
| Capital Expenditures | -2.32M |
| Free Cash Flow | -224.73M |
| FCF Per Share | -2.54 |
Margins
Energenesis Biomedical CO.,LTD. operates with a gross margin of 76.00, reflecting its pricing power and cost economics. The operating margin of -3,587.11 and net profit margin of -3,367.24 provide insight into operational efficiency.
| Gross Margin | 76.00 |
| Operating Margin | -3,587.11 |
| Pretax Margin | -3,367.24 |
| Profit Margin | -3,367.24 |
| EBITDA Margin | -3,587.11 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -10.52 |
| FCF Yield | -5.80 |
Scores
Energenesis Biomedical CO.,LTD. posts an Altman Z-Score of 42.60, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 42.60 |